MARKET

MCRB

MCRB

Seres
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.36
+1.11
+4.40%
Closed 19:48 09/25 EDT
OPEN
25.25
PREV CLOSE
25.25
HIGH
26.49
LOW
25.03
VOLUME
586.72K
TURNOVER
--
52 WEEK HIGH
33.00
52 WEEK LOW
2.520
MARKET CAP
2.31B
P/E (TTM)
-24.7396
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BiomX: A Phage Platform Play
BiomX is focused on large market opportunities using the unique approach of manipulating the microbiome utilizing phage therapy.BX001 will begin Phase II trials in 2021 in acne and if successful, marketing will be handled by a global cosmetic company.BX002 will enter the clinic in 2020 in a Phase 1 study in inflammatory bowel disease with a data read out by year end.BiomX is a high risk, high return investment only suitable for investors seeking this profile.
Seekingalpha · 2d ago
Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T.
Business Wire · 6d ago
Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers
Gainers: Cassava Sciences (SAVA) +41%, Evogene (EVGN) +26%, AlloVir (ALVR) +15%, Abeona Therapeutics (ABEO) +15%, Sonoma Pharmaceuticals (SNOA) +14%.Losers: Ayala Pharmaceuticals (AYLA) -12%, Clovis Oncology (CLVS) -10%, Checkpoint Therapeutics (CKPT) -9%, Seres Therapeutics (MCRB) -8%, Innate Pharma (IPHA) -5%.
Seekingalpha · 09/18 14:56
Seres Therapeutics to Present at Upcoming Investor Conferences
Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences:
Business Wire · 09/14 12:00
Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109
Business Wire · 09/11 12:00
Seres Therapeutics Reports FDA Correspondence Following SER-109 Phase 3 Results: FDA Reaffirmed Prior Guidance Regarding Efficacy Requirements
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s
Benzinga · 09/11 11:01
The Seres Therapeutics (NASDAQ:MCRB) Share Price Has Soared 590%, Delighting Many Shareholders
While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...
Simply Wall St. · 08/21 19:24
Benzinga's Top Upgrades, Downgrades For August 18, 2020
Upgrades * Wedbush upgraded the previous rating for Best Buy Co Inc (NYSE: BBY) from Neutral to Outperform. For the first quarter, Best Buy Co had an EPS of $0.67, compared to year-ago quarter EPS of $1.02. At the moment, the stock has a 52-week-high of $111.39 and a 52-week-low of $48.10. Best Buy
Benzinga · 08/18 14:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MCRB. Analyze the recent business situations of Seres through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MCRB stock price target is 33.21 with a high estimate of 42.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 72.71M
% Owned: 82.89%
Shares Outstanding: 87.72M
TypeInstitutionsShares
Increased
39
6.25M
New
27
623.73K
Decreased
15
2.68M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Stephen Berenson
President/Chief Executive Officer/Director
Eric Shaff
Chief Financial Officer/Senior Vice President - Finance/Chief Accounting Officer
Marcus Chapman
Executive Vice President/Chief Technology Officer
John Aunins
Executive Vice President/Chief Scientific Officer
Matthew Henn
Executive Vice President/Secretary
Thomas DesRosier
Executive Vice President
Lisa von Moltke
Executive Vice President
Terri Young
Independent Director
Dennis Ausiello
Independent Director
Gregory Behar
Independent Director
Paul Biondi
Independent Director
Willard Dere
Independent Director
Kurt Graves
Independent Director
Richard Kender
Independent Director
Meryl Zausner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MCRB
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.